HIV / AIDS
Dolutegravir Active against Raltegravir-resistant HIV, Granted FDA Priority Review
- Details
- Category: HIV Treatment
- Published on Wednesday, 20 February 2013 00:00
ViiV Healthcare announced last week that the U.S. Food and Drug Administration has given a priority review designation for its investigational HIV integrase inhibitor dolutegravir, which has demonstrated good efficacy in both treatment-naive and treatment-experienced people.
Updated HIV Treatment Guidelines Include Stronger Recommendation for Acute Infection
- Details
- Category: HIV Treatment
- Published on Friday, 15 February 2013 00:00
On February 12, 2013, the U.S. Department of Health and Human Services antiretroviral therapy (ART) guidelines panel issued an update to the adult and adolescent HIV treatment guidelines. Among the key changes are additional information about the most recently approved antiretroviral agents and a recommendation that newly infected people with HIV should be offered combination ART.
Atazanavir (Reyataz) Label Update Adds Kidney Warning, Drug Interactions
- Details
- Category: HIV Treatment
- Published on Tuesday, 12 February 2013 00:00
Product label information for the HIV protease inhibitor atazanavir (brand name Reyataz) was recently revised to include new warnings about cholelithiasis or gall bladder stones and interstitial nephritis (a type of kidney inflammation), as well as interactions with several other medications, including the hepatitis C virus protease inhibitor boceprevir (Victrelis).
Even Small Viral Load Reduction Is Beneficial for People with Highly Resistant HIV
- Details
- Category: HIV Treatment
- Published on Friday, 15 February 2013 00:00
Antiretroviral therapy (ART) can help raise CD4 T-cell counts even if it does not produce undetectable HIV RNA due to extensive drug resistance, indicating that treatment likely has immunological benefits even for people with few therapeutic options, according to a report in the March 1, 2013 Journal of Infectious Diseases.
IL-7 in Semen May Facilitate HIV Transmission during Vaginal Sex
- Details
- Category: HIV Prevention
- Published on Tuesday, 12 February 2013 00:00
The presence of the naturally occurring cytokine interleukin 7 (IL-7) in semen enhances HIV replication by stimulating CD4 T-cell replication, which may increase the likelihood of infection of the female genital tract during sex, according to a study published online February 7, 2013, in the open-access journal PLoS Pathogens.
People with HIV Have Higher Rates of Non-AIDS Malignancies, Skin Cancer
- Details
- Category: Cancer/Malignancies
- Published on Tuesday, 12 February 2013 00:00
The incidence of non-AIDS-defining cancers has increased among people with HIV in the era of effective antiretroviral treatment, including malignancies caused by viruses such as human papillomavirus (HPV), and squamous cell non-melanoma skin cancer, according to 2 recently published studies.
ViiV Announces Halt to Lersivirine Development
- Details
- Category: HIV Treatment
- Published on Wednesday, 06 February 2013 00:00
On February 5, 2013, ViiV Healthcare announced that the company has decided to stop the development program investigating its experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine.
More Articles...
- February 7 is National Black HIV/AIDS Awareness Day
- Only 1 in 5 Medicaid Users Linked to Care Within a Year After HIV Diagnosis
- New HIV NNRTI Lersivirine Matches Efavirenz in Phase 2b Trial
- Low-Level HIV Viral Load Linked to Gut Leakage and Inflammation
- Gilead Starts Phase 3 Trials for New HIV Pro-drug Tenofovir Alafenamide
Web Design and Development by